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Successful clinical trials of antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV 
infection have been reported in heterosexual men and women, men who have sex with men 
(MSM), and injection drug users1. A daily oral drug regimen containing nucleoside reverse 
transcriptase inhibitors (NRTIs) tenofovir disoproxil fumarate (TDF) alone or in 
combination with emtricitabine (FTC) have been effective when participant adherence is 
high1. Analysis of PrEP dosing patterns estimate taking at least four TDF doses per week 
provides 96% protection from HIV infection and at least two doses per week provides 76% 
protection in MSM and transgender women2, though some estimate more frequent dosing in 
heterosexual women may be needed3. TDF and FTC require phosphorylation in HIV target 
cells to tenofovir-diphosphate (TFV-DP) and emtricitabine-triphosphate (FTC-TP) to 
provide PrEP protection as competitive analogs of naturally occurring deoxyadenosine 
triphosphate (dATP) and deoxycytidine triphosphate (dCTP), respectively. However, it is 
unclear if physiological conditions that increase dNTP concentrations can affect 
pharmacokinetics (PK) and pharmacodynamics (PD) of NRTIs. This may be particularly 
relevant when cellular deoxynucleoside triphosphate (dNTP) pools in HIV target cells 
increase in response to immune activation. Decreased ratios of phosphorylated NRTIs to 
their respective dNTPs have been associated with cell activation in vitro and in nonhuman 
primate studies4,5, yet this observation remains unexplored in PK and PD studies that 
measured intracellular drug6-8. The study presented here compared dATP and dCTP 
concentrations to TFV-DP and FTC-TP in peripheral blood mononuclear cell (PBMCs) of 
persons using daily oral Truvada™ during a successful HIV PrEP study. We further 
examined if variations among intracellular drug:dNTP ratios were related to lymphocyte 
activation.
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PBMCs were isolated from 12 persons before (T0) and 2, 4, and 8 hours following an 
observed single daily dose of Truvada™ during their 3-month study visit for the TDF2 PrEP 
Trial, so samples should be at pseudo-steady-state9. Prescribed dosing at bedtime resulted in 
assumed T0 sampling approximately 18-24 hours following the previous dose. Intracellular 
active drug metabolites TFV-DP, FTC-TP, and their natural substrates, dATP and dCTP, 
respectively, were measured in methanol extracts of PBMCs by high performance liquid 
chromatography-tandem mass spectrometry as previously described5,10. A wide range of 
presumed steady-state intracellular concentrations was observed for TFV-DP (median = 64 
fmol/106 PBMC; range: 20-387 fmol/106 PBMC) and FTC-TP (median = 6451 fmol/106 
PBMC; range: 1361-30310 fmol/106 PBMC), yet concentrations of TFV-DP and FTC-TP 
were highly correlated (Spearman Rank Order, ρ = 0.860, p < 0.001).
To estimate adherence to PrEP dosing in our substudy, we compared our intracellular TFV-
DP and FTC-TP concentrations to those reported in the HPTN 066 study of observed 
Truvada™ dosing7. This comparison estimated that all of our substudy participants were 
taking four or more Truvada™ doses per week (TFV-DP >19 fmol/106 PBMC, FTC-TP 
>600 fmol/106 PBMC), while 10 had TFV-DP concentrations (>36 fmol/106 PBMC) and 11 
had FTC-TP concentrations (>2200 fmol/106 PBMC) consistent with daily dosing. Within 
the 8 hour sampling window after the observed Truvada™ dose, all 12 participants' TFV-DP 
and FTC-TP concentrations were at or above those reported for observed daily dosing in 
HPTN 066.
There were also wide ranges of concentrations for both dATP (median = 430 fmol/106 
PBMC; range: 89-2375 fmol/106 PBMC) and dCTP (median = 776 fmol/106 PBMC; range: 
226-1635 fmol/106 PBMC) in the PBMC samples. However, these nucleotide concentrations 
were highly correlated with their respective intracellular drug analog concentrations in the 
pre-dose sample (T0) (TFV-DP and dATP, ρ = 0.881, p < 0.001; FTC-TP and dCTP, ρ = 
0.909, p < 0.001). The ratio of phosphorylated drug to dNTP in PBMCs was lower for TFV-
DP:dATP (median, 0.18:1) than for FTC-TP:dCTP (median, 8.73:1). The TFV-DP:dATP 
ratio remained mostly unchanged throughout the 8 hour post-dose sampling period (Figure 
1A) while the FTC-TP:dCTP ratio increased from pre-dose (T0) to 4 hours (p < 0.001) 
before declining at 8 hours post dose (Figure 1B). Plasma TFV and FTC concentrations at 
these time points peaked at 2-4 hours post-dose as expected and were not correlated with 
TFV-DP, FTC-TP, or dNTP levels (data not shown).
To assess whether cell activation was associated with intracellular drug concentrations and 
NRTI:dNTP ratios, we measured the percentage of CD4+ lymphocytes expressing CD38 and 
HLA-DR in cryopreserved T0 PBMC samples using a Multitest antibody cocktail (CD4/
CD38/CD3/HLA-DR, BD Biosciences, San Jose, CA) and FACSCalibur flow cytometer 
(BD Biosciences). The CD38+/HLA-DR+ population ranged from 4 to14% of CD4+ 
lymphocytes and inversely correlated with TFV-DP:dATP ratios of PBMCs (ρ= -0.608, p = 
0.033; Figure 1C). However, neither FTC-TP:dCTP ratios, individual intracellular drug 
concentrations, nor dATP or dCTP concentrations were correlated with CD38+/HLA-DR+ 
expression (all p > 0.05, data not shown).
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The results of our substudy provide new intracellular PK data for heterosexual adults 
enrolled in a successful PrEP trial of daily oral dosing of Truvada™. The intracellular TFV-
DP and FTC-TP concentrations we observed were similar in range to steady-state 
concentrations reported for HIV-negative participants in a pharmacokinetic study (TFV-DP 
mean, 103 fmol/106 cells; FTC-TP mean, 6 pmol/106 cells)11 which are associated with 
dosing regimens providing protection among MSM participants in a PrEP study that 
demonstrated a reduced risk for acquiring HIV6. However, analyses of larger data sets are 
needed to adequately determine if the TFV-DP or FTC-TP concentrations and NRTI:dNTP 
ratios we report reflect predictive PrEP-effective concentrations for at-risk heterosexual 
persons.
The pseudo-steady-state NRTI:dNTP ratios reported here remained consistent throughout a 
broad range of intracellular drug concentrations in PBMCs, suggesting NRTI:dNTP ratios 
may not vary widely among adherent PrEP study participants. Yet, within our limited data 
set, lower TFV-DP:dATP ratios associated with increased PBMC activation suggesting 
immune activation may influence intracellular ratios in vivo similar to that reported for 
PBMC activation in vitro4. Immune activation may increase dATP or decrease TFV-DP 
thereby reducing the TFV-DP:dATP ratio, but no consistent trend was observed for either 
possibility in the study reported here. FTC-TP:dCTP ratios were not correlated with cell 
activation in this study which may be related to metabolic factors that may include the 
markedly shorter intracellular half-life reported for FTC-TP (17 hours) compared to TFV-DP 
(5.6 days)12. Previous studies indicated dNTP pools in PBMCs decline following initiation 
of TDF/FTC therapy in both HIV-negative and HIV-positive individuals13, and TDF/FTC 
therapy can reduce immune activation among HIV-negative individuals14. These studies and 
the results presented here suggest a complex interplay between antiretroviral therapy and 
cell activation establishes drug:dNTP ratios in PBMCs.
Limitations to our study are that drug:dNTP measurements were performed using the entire 
pool of PBMCs, while activation was examined only for the subpopulation of CD4+ PBMCs 
and our analysis did not include genital or rectal mucosal tissues where sexually transmitted 
virus exposure occurs. While the role of mucosal tissue drug concentrations and drug:dNTP 
ratios in protecting against HIV has yet to be defined, a wide range of TFV-DP:dATP ratios 
in human mucosal tissues8 and reduced TFV-DP:dATP ratios in rectal lymphocytes in a non-
human primate model5 have been reported. Mucosal NRTI:dNTP ratios are likely more 
variable than those observed in PBMCs, yet clinical trials continue to report high levels of 
protection among adherent participants indicating that within these widely fluctuating ratios, 
a high degree of efficacy is maintained9. Nevertheless, examination of NRTI:dNTP ratios at 
mucosal sites of HIV exposure and their role in PrEP efficacy is warranted, especially under 
physiological conditions that increase immune activation such as sexually transmitted 
infections.
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Intracellular tenofovir-diphosphate and emtricitabine-triphosphate concentrations correlate 
with corresponding natural substrate concentrations. Intracellular ratios concentrations of 
NRTI and dNTP were calculated in PBMCs pre-dose (T0) and 2, 4 or 8 hours post-dose for 
TFV-DP:dATP (A) and FTC-TP:dCTP (B). The ratio of TFV-DP to dATP concentrations 
were calculated for T0 samples and cellular activation was determined by the percentage of 
CD4+ lymphocytes stained CD38+/HLA-DR+ by flow cytometry (C).
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